Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG Study-Analysis of patient reported outcomes (PRO) on chemotherapy randomization Meeting Abstract
| Authors: | Basen-Engquist, K.; Huang, H. Q.; Herzog, T. J.; Armstrong, D. K.; Sabbatini, P.; Walker, J. L.; Kim, B. G.; Fujiwara, K.; Tewari, K. S.; O'Malley, D. M.; Coleman, R. L. |
| Abstract Title: | Randomized phase III trial of carboplatin/paclitaxel alone (CP) or in combination with bevacizumab followed by bevacizumab (CPB) and secondary cytoreduction surgery in platinum-sensitive recurrent ovarian cancer: GOG0213, an NRG Oncology/GOG Study-Analysis of patient reported outcomes (PRO) on chemotherapy randomization |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036901185 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.5525 |
| Notes: | Meeting Abstract: 5525 -- Source: Wos |
